Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care

This is a phase 2 study of the drug ketamine for the treatment of depression in cancer patients receiving palliative care.

The purpose of this study is to see how useful the drug is at decreasing the severity of depression these patients. Ketamine will be given through the nose.

Topic Depression
Compound Ketamine
Country Canada
Visit trial
Status Completed
Results Published Yes
Start date 16 July 2018
End date 27 November 2021
Phase Phase II
Design Open
Type Interventional
Participants 20
Sex All
Age 18- 99
Therapy No

Trial Details

This is a phase 2 study of the drug ketamine for the treatment of depression in cancer patients receiving palliative care. The purpose of this study is to see how useful the drug is at decreasing the severity of depression these patients. Ketamine will be given through the nose.

Trial Number NCT03410446

Sponsors & Collaborators

University Health Network Toronto
University Health Network is a public research and teaching hospital network in Toronto. The Nikean Psychedelic Psychotherapy Research Centre was established in 2021.

Papers

A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study)
This open-label study (n=20) finds that ketamine (intranasal, 3x, 50-150mg) reduced depression in patients with cancer who were receiving palliative care. On day eight (one day after the last dose), the response and remission rates were 70% and 45%, respectively. The effects were partially sustained in the second week.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.